T cells are the immune system’s frontline fighters. When they detect danger, they rapidly multiply and transform into ...

The deal gives Cullinan T cell engagers aimed at BCMA and CD19, which drugmakers are exploring as possible targets for ...

A retrospective study presented at the recent American Society of Clinical Oncology (ASCO) meeting suggested that patients ...

Cabaletta announced promising results of its lead T-cell therapy candidate targeting autoimmune diseases. Eagles owner ...

A novel blood test could help diagnose celiac disease more straightforwardly, without the need to potentially trigger ...

CAR T-cell therapy, a type of treatment that weaponizes the body’s immune system and was originally developed to treat cancer ...

Genrix’s velinotamig complements Cullinan’s own pipeline, according to William Blair, which added that the deal will put ...

In modern immunotherapy, modified immune cells are introduced into the body to attack tumors and other targets. Researchers ...

A new study will evaluate the safety and efficacy of universal allogeneic anti-CD19/BCMA CAR T-cells in relapsed or refractory autoimmune diseases including antineutrophil cytoplasmic antibody ...

CD19-CAR T-cell treatment is a novel option of deep B cell depletion with promising results across different rheumatologic and musculoskeletal diseases (RMD). This and other cell-depleting approaches ...